Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Primary listing
Employees
350
Headquarters
Website
HALO Metrics
BasicAdvanced
$8.9B
17.37
$4.37
1.17
-
Price and volume
Market cap
$8.9B
Beta
1.17
52-week high
$77.60
52-week low
$42.01
Average daily volume
2M
Financial strength
Current ratio
8.361
Quick ratio
6.438
Long term debt to equity
462.233
Total debt to equity
462.233
Interest coverage (TTM)
37.96%
Profitability
EBITDA (TTM)
758.6
Gross margin (TTM)
77.49%
Net profit margin (TTM)
47.28%
Operating margin (TTM)
57.92%
Effective tax rate (TTM)
19.48%
Revenue per employee (TTM)
$3,370,000
Management effectiveness
Return on assets (TTM)
21.21%
Return on equity (TTM)
179.14%
Valuation
Price to earnings (TTM)
17.366
Price to revenue (TTM)
8.004
Price to book
26.8
Price to tangible book (TTM)
-19.8
Price to free cash flow (TTM)
17.449
Free cash flow yield (TTM)
5.73%
Free cash flow per share (TTM)
4.345
Growth
Revenue change (TTM)
34.97%
Earnings per share change (TTM)
68.93%
3-year revenue growth (CAGR)
34.22%
10-year revenue growth (CAGR)
27.11%
3-year earnings per share growth (CAGR)
19.82%
10-year earnings per share growth (CAGR)
30.35%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
Bulls say / Bears say
Total Q2 revenue climbed 41% year-over-year to $326 million, with royalty revenue surging 65% to $206 million, demonstrating robust adoption of the high-margin ENHANZE platform (Reuters).
Management raised full-year 2025 guidance a second time, projecting revenue of $1.275 billion to $1.355 billion and adjusted EBITDA of $865 million to $915 million, underscoring confidence in sustained growth (Reuters).
Net income increased 77% to $165 million in Q2, reflecting strong operating leverage and efficiency gains from expanding royalties and collaboration revenues (Reuters).
CMS draft guidance under the IRA could subject ENHANZE-based combination products to price negotiations just 13 years after original drug approval rather than combination approval, threatening royalty protections and future revenue streams (Reuters).
Halozyme’s key ENHANZE patents expire in 2027, raising long-term sustainability concerns as biosimilar competition and non-injectable delivery innovations could erode its royalty base once exclusivity lapses (Seeking Alpha).
Halozyme faces ongoing patent litigation after filing suit against Merck over its subcutaneous Keytruda formulation, exposing the company to costly legal battles and uncertain royalty outcomes if patents are invalidated (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $8.9B as of September 18, 2025.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 17.37 as of September 18, 2025.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.